CJC 1295/IPAMORELIN

If you’ve been looking for an effective growth hormone that doubles as a stimulant for fat loss, look no further than CJC 1295/Ipamorelin. CJC 1295/Ipamorelin is the combination of two compounds, CJC 1295 and Ipamorelin. It is a safe and increasingly popular growth hormone among patients, and is recommended by many qualified physicians. 

Both CJC 1295 and Ipamorelin are similar in function. CJC 1295 is prescribed by physicians as a growth hormone releasing hormone (GHRH) analog while Ipamorelin is prescribed as a selective Growth Hormone Secretagogue. Both of these act on the pituitary gland. 

CJC 1295/Ipa works in a simple yet effective way. It has been shown to increase growth hormones as well as IGF-I secretion by acting on two different families of receptors. CJC 1295/Ipa stimulates growth hormone secretion and will keep a steady increase of HGH and IGF-1 with no increase in prolactin, leading to fat loss and increased protein synthesis thereby promoting growth.

CJC 1295/Ipa is an improvement upon previous growth hormones. CJC 1295 is a tetrasubstituted 30-amino acid peptide hormone, primarily functioning as a growth hormone releasing hormone (GHRH) analog. CJC 1295 outperforms the older and outdated GHRH, Sermorelin. The binding life of Sermorelin ranges from 8-12 minutes, whereas the half-life of CJC 1295 extends to 30 minutes. Sermorelin’s decay decreases with time and the body produces antibodies to Sermorelin.

Benefits: 

  • Increase in bone density
  • Strengthens cardiovascular system
  • Increase muscle mass
  • Improve ability to burn fat
  • Increase sex drive
  • Improve recovery and repair from injuries
  • Regenerate nerve tissues
  • Strengthen immune system
  • Improve cognition and memory

 

CJC 1295/Ipa has been thoroughly research-tested to prove its safety and effectiveness. Various experiments have been conducted to test the pharmacokinetics (the effect the body has on the drugs) of CJC 1295/Ipamorelin in vivo and the Journal of Clinical Endocrinology & Metabolism has reported dose-dependent increases in mean plasma GH concentrations by 2-10 fold for more than 6 days and increased IGF-1 concentrations 1.5-3 fold for 9-11 days after a single injection. Mean half-life was shown to be 5.8-8.1 days, also after multiple doses mean IGF-1 levels remained above baseline for up to 28 days. No serious adverse reactions were reported in any group. This growth hormone has been shown to be a safe and proven solution for many patients. 

Clinical Research

  1. In 2005 a research study was conducted on people whose ages ranged from 21 to 61 years old to study the growth hormone secretion and safety of CJC 1295. The study was published in 2006 and the results and conclusions are as followed: 

Results: After a single injection of CJC-1295/Ipamorelin, there were dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 d or more and in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9-11 d. After multiple CJC-1295 doses, mean IGF-I levels remained above baseline for up to 28 d. Conclusion: Subcutaneous administration of CJC-1295/Ipa resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe.

If you’ve been looking for an effective growth hormone that doubles as a stimulant for fat loss, Contact Foster Medical today! Make an appointment with our qualified physician to discuss  CJC 1295/Ipamorelin and it’s recommended use.